NCT07376980

Brief Summary

The goal of this clinical trial is to learn whether a modified single-stapled anastomosis (MST) can reduce anastomotic leakage compared with the conventional double-stapled technique (DST) in adult patients undergoing laparoscopic or robotic low anterior resection for rectal cancer. The main questions it aims to answer are:

  • Does MST lower the incidence of anastomotic leakage after rectal cancer surgery?
  • Does MST improve short-term surgical outcomes compared with DST? Researchers will compare the MST group with the DST group to see if MST leads to fewer anastomotic leaks and safer postoperative recovery. Participants will: Receive either MST or DST during minimally invasive rectal cancer surgery Undergo routine postoperative CT scans within one month after surgery to check for symptomatic or asymptomatic anastomotic leakage Attend scheduled follow-up visits and standard postoperative assessments as part of routine rectal cancer care

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
450

participants targeted

Target at P75+ for not_applicable

Timeline
56mo left

Started Dec 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

6 active sites

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress8%
Dec 2025Dec 2030

First Submitted

Initial submission to the registry

December 3, 2025

Completed
17 days until next milestone

Study Start

First participant enrolled

December 20, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 29, 2026

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2027

Expected
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2030

Last Updated

January 29, 2026

Status Verified

January 1, 2026

Enrollment Period

2 years

First QC Date

December 3, 2025

Last Update Submit

January 26, 2026

Conditions

Keywords

Rectal CancerTotal Mesorectal ExcisionLow Anterior ResectionAnastomotic LeakAnastomosis, SurgicalStapled anastomosisModified Single-Stapled TechniqueMinimally Invasive Rectal Surgery

Outcome Measures

Primary Outcomes (1)

  • Anastomotic leakage

    Anastomotic leakage will be assessed within 30 days after surgery using clinical evaluation and routine abdominopelvic computed tomography (APCT). Leakage is defined as any defect in the anastomosis that results in communication between the inside of the bowel and the surrounding tissue. Diagnostic criteria include clinical symptoms (such as fever, abdominal pain, or drainage contents), abnormal laboratory findings, or radiologic evidence of leakage on APCT. All leaks will be classified according to the grading system. * Grade A: Leakage requiring no active therapeutic intervention. * Grade B: Leakage requiring non-surgical management, such as antibiotics or percutaneous drainage. * Grade C: Leakage requiring reoperation. Routine postoperative CT for all participants ensures consistent and standardized detection of both symptomatic and asymptomatic leaks.

    within 30 days after surgery

Study Arms (2)

Modified single-stapled anastomosis technique

EXPERIMENTAL

Participants assigned to this arm will undergo minimally invasive low anterior resection using the modified single-stapled technique. After rectal resection, the two ends of the linear staple line of stump are approximated toward the center using a barbed suture. The circular stapler spike is introduced through the center of the staple line to ensure complete resection of the linear staple line, eliminating staple-line intersections. The reaminder of the procedure, including total mesorectal excision, follows standard oncologic principles.

Procedure: Modified single-stapled anastomosis technique

Double-stapled anastomosis technique

NO INTERVENTION

Participants assigned to this arm will undergo minimally invasive low anterior resection using the conventional double-stapled technique. The rectum is transected with linear stapler, followed by transanal introduction of a circular stapler to create an end-to-end anastomosis. The procedure represents current standard practice for low anterior resection in rectal cancer.

Interventions

This intervention applies a modified single-stapled anastomosis specifically to low anterior resection (LAR), where the technique has not been previously evaluated in a randomized controlled trial. Although similar concepts have been explored in anterior resection, their application in LAR is technically more challenging due to the deeper pelvic working space and more limited access to the rectal stump. In earlier studies, approximation of the linear staple line was performed through a Pfannelstein incision or mini-laparotomy incision during specimen extraction. In contrast, this trial utilizes a fully intracorporeal approach.

Also known as: Single-stapled anastomosis, Modified single-stapled anastomosis, Dog-ear-free anastomosis, Single-stapling technique, Modified double-stapling technique, Dog-ear closure technique
Modified single-stapled anastomosis technique

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients with rectal cancer who are scheduled to undergo laparoscopic or robotic low anterior resection
  • histologically confirmed rectal adenocarcinoma located within 15cm from anal verge.
  • ECOG performance status of 0 to 2
  • Any clinical stage

You may not qualify if:

  • Who have significant comorbidities or history of abdominal surgeries that would preclude a minimally invasive approach
  • Bowel obstruction for perforation requiring emergency surgey
  • Concurrent, or recent treatment for colorectal or other malignancies within the past five years
  • Presence of inflammatory bowel diseases
  • Hereditary colorectal cancer syndrome

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

St. Vincent's Hospital

Suwon, Gyeonggi-do, 16247, South Korea

Location

Kyungpook National University Chilgok Hospital

Daegu, Gyeongsangbuk-do, 41404, South Korea

Location

Kyung Hee University Hospital

Seoul, 02447, South Korea

Location

Korea University Anam Hospital

Seoul, 02841, South Korea

Location

Seoul National University Hospital

Seoul, 03080, South Korea

Location

Severance Hospital

Seoul, 03722, South Korea

Location

MeSH Terms

Conditions

Rectal NeoplasmsAnastomotic Leak

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesIntestinal DiseasesRectal DiseasesPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Jin Kim, M.D., Ph.D

    Korea University Anam Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
No additional parties.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This study uses a parallel assignment interventional model. Participants will be randomly allocated in a 1:1 ratio to one of two dependent surgical intervention arms: MST or DST. Each participatns will undergo only assigned surgical technique without crossover betwen groups.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 3, 2025

First Posted

January 29, 2026

Study Start

December 20, 2025

Primary Completion (Estimated)

December 30, 2027

Study Completion (Estimated)

December 30, 2030

Last Updated

January 29, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

IPD will not be shared because the dataset contains sensitive clinical information, and secondary distribution is not permitted under the terms of institutional review board approvals and patient consent. Data access is restricted to the study investigators to protect participant privacy.

Locations